Trial ID or NCT#

NCT02184195

Status

recruiting iconRECRUITING

Purpose

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

Official Title

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

Eligibility Criteria

Ages Eligible for Study: 18 Years to 130 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

James Ford
James Ford
Medical oncologist, Gastrointestinal specialist, Cancer geneticist
Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics

Contact us to find out if this trial is right for you.

CONTACT

Ivy Lau
(650) 721-8899